Welcome visitor Log In - or - Register
0 items /
View Cart
Check Out
four ways
Quick Search:
Skip Navigation LinksHome > Glutaminase Inhibitor > CB-839 (Telaglenastat)
CB-839 (Telaglenastat)
CB-839 (Telaglenastat) is a clinical-stage, orally bioavailable inhibitor of the glutaminase 1 (GLS1) splice variants, kidney-type (KGA) and glutaminase C (GAC). It inhibits human recombinant GAC (IC50 < 50 nM), and GLS1 activity in tissue homogenates (IC50s = 28 and 23 nM, respectively for brain and kidney), but not GLS2 (IC50 > 1,000 nM from liver). Displays antiproliferative activity against the triple-negative breast cancer (TNBC) cell lines HCC1806 and MDA-MB-231 (IC50s = 49 and 26 nM, respectively) but not against estrogen receptor-positive T47D cells (IC50 > 1,000 nM). In a patient-derived TNBC mouse xenograft model, CB-839 (200 mg/kg, p.o.) inhibits tumor growth by 61% relative to vehicle control. It also possesses antiproliferative properties in vitro against acute myeloid leukemia (AML) and in synergy with erlotinib (Prod No. CT-EL002) in EGFR-driven non-small cell lung cancer (NSCLC) in vitro and in xenografts (ref 1, 2, 3).
Catalog NO: CT-CB839
Synonym: CB839, Telaglenastat
CAS NO: 1439399-58-2
Mol. Formula: C26H24F3N7O3S
MW: 571.6
** 99.9% Purity, recrystallized, made for In vivo studies. White to off-white crystalline solid (all Qc docs are attached), with a spot-on elemental analysis. Same Day Shipping.